CIK 0001619856 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Caribou Biosciences, Inc.
Sign in to watch- Ticker
- CRBU
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453728228
- Phone
- 510-982-6030
- Business address
- 2929 7TH STREET, SUITE 105, BERKELEY, CA, 94710
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-04 | Kanner Steven Chief Scientific Officer | Option exercise | +9,171 | $2.69 | $25K | 226,090 |
| 2022-03-04 | Kanner Steven Chief Scientific Officer | Option exercise | +1,549 | $4.11 | $6K | 227,639 |
| 2022-03-04 | Kanner Steven Chief Scientific Officer | Option exercise · Option to purchase Common Stock | −9,171 | 122,963 | ||
| 2022-03-04 | Kanner Steven Chief Scientific Officer | Option exercise · Option to purchase Common Stock | −1,549 | 230,365 | ||
| 2022-02-08 | O'Byrne Jason Chief Financial Officer | Option exercise | +24,336 | $4.11 | $100K | 24,336 |
| 2022-02-08 | O'Byrne Jason Chief Financial Officer | Option exercise · Option to purchase Common Stock | −24,336 | 412,865 | ||
| 2022-01-26 | Haurwitz Rachel E. President and CEO | Option exercise | +10,000 | $2.96 | $30K | 10,000 |
| 2022-01-26 | Haurwitz Rachel E. President and CEO | Option exercise · Option to purchase Common Stock | −10,000 | 126,350 | ||
| 2022-01-26 | Haurwitz Rachel E. President and CEO | Option exercise | +10,000 | $2.96 | $30K | 3,359,395 |
| 2022-01-26 | Haurwitz Rachel E. President and CEO | Option exercise · Option to purchase Common Stock | −10,000 | 126,350 | ||
| 2022-01-25 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award | +60,000 | 65,000 | ||
| 2022-01-25 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award · Option to purchase common stock | +161,250 | 161,250 | ||
| 2022-01-11 | Fischesser Ryan VP of Finance and Controller | Purchase | +569 | $2.69 | $2K | 102,264 |
| 2022-01-11 | Fischesser Ryan VP of Finance and Controller | Purchase | +6,818 | $4.11 | $28K | 109,082 |
| 2022-01-11 | Fischesser Ryan VP of Finance and Controller | Option exercise · Option to purchase Common Stock | −569 | 6,815 | ||
| 2022-01-11 | Fischesser Ryan VP of Finance and Controller | Option exercise · Option to purchase Common Stock | −6,818 | 20,452 | ||
| 2021-12-20 | Whiting Nancy Director | Grant or award · Option to purchase Common Stock | +13,060 | 13,060 | ||
| 2021-12-20 | Zheng Ran Director | Grant or award · Option to purchase Common Stock | +13,750 | 13,750 | ||
| 2021-12-20 | Whiting Nancy Director | Grant or award · Option to purchase Common Stock | +13,750 | 13,750 | ||
| 2021-12-20 | Sacks Natalie Director | Grant or award · Option to purchase Common Stock | +27,500 | 27,500 |
Page 7 of 9 · 177 trades